Home Articles List Article Information
ALEXMED ePosters
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
atia, E., Mokhtar, A., eldabah, N., Sadaka, M., hassanein, M. (2021). VALUE OF COPEPTIN MEASUREMENT AS A NOVEL BIOMARKER FOR PROGNOSIS INACUTE HEART FAILURE. ALEXMED ePosters, 3(2), 4-5. doi: 10.21608/alexpo.2021.62137.1119
eman atia; Ahmed Mokhtar; Nermeen eldabah; Mohammed A Sadaka; mahmoud mohammed hassanein. "VALUE OF COPEPTIN MEASUREMENT AS A NOVEL BIOMARKER FOR PROGNOSIS INACUTE HEART FAILURE". ALEXMED ePosters, 3, 2, 2021, 4-5. doi: 10.21608/alexpo.2021.62137.1119
atia, E., Mokhtar, A., eldabah, N., Sadaka, M., hassanein, M. (2021). 'VALUE OF COPEPTIN MEASUREMENT AS A NOVEL BIOMARKER FOR PROGNOSIS INACUTE HEART FAILURE', ALEXMED ePosters, 3(2), pp. 4-5. doi: 10.21608/alexpo.2021.62137.1119
atia, E., Mokhtar, A., eldabah, N., Sadaka, M., hassanein, M. VALUE OF COPEPTIN MEASUREMENT AS A NOVEL BIOMARKER FOR PROGNOSIS INACUTE HEART FAILURE. ALEXMED ePosters, 2021; 3(2): 4-5. doi: 10.21608/alexpo.2021.62137.1119

VALUE OF COPEPTIN MEASUREMENT AS A NOVEL BIOMARKER FOR PROGNOSIS INACUTE HEART FAILURE

Article 77, Volume 3, Issue 2, June 2021, Page 4-5  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2021.62137.1119
View on SCiNiTO View on SCiNiTO
Authors
eman atia email 1; Ahmed Mokhtar2; Nermeen eldabah1; Mohammed A Sadakaorcid 1; mahmoud mohammed hassanein3
1khartum Square, Azarita, Alexandria, Egypt
2faculty of medicine, alexandria university, cardiology and angiology department
3Cardiology department, faculty of medicine, Alexandria University, khartum Square, Azarita, Alexandria, Egypt.
Abstract
Abstract
Background: Copeptin, C-terminal segment of pro-arginine vasopressin, is expected to be a strong novel biomarker for prognosis in acute heart failure (AHF).
Participants & Methods: The study included 45 patients with acute decompensated heart failure(ADHF) to assess the relationship of serum copeptin level on admission and 72 hours after admission with adverse cardiac events (death, re-hospitalization and arrhythmias) in patients hospitalized for (ADHF) between May 2019 and November 2019 with median follow up period 6 months.
Results: In this study,15 patients died, re-admission occurred in 22 patients and arrhythmias were documented in 14 patients with atrial fibrillation (n=9) and ventricular arrhythmias (n=5). Mortality rate was higher among elder smoker patients with higher heart rate, low left ventricular systolic function, higher rates of arrhythmias, impaired kidney function and high copeptin level.
Furthermore, copeptin level at day 1 with cutoff value of ˃2.54 pmol/l predicted mortality with sensitivity 86.67% and specificity 53.33% while copeptin level at day 3 with cutoff value ˃ 2.74 pmol/l predicted mortality with sensitivity 93.33% and specificity 83.33%.
Finally, change in copeptin level between day 1 and day 3 was associated with increased mortality. (p˂0.001)
Conclusion: Copeptin is suggested to be a strong biomarker to predict adverse clinical outcomes in patients with acute decompensated heart failure including death.
Keywords
copeptin; heart failure; prognosis; adverse events; vasopressin
Supplementary Files
Statistics
Article View: 239